Lumosa Therapeutics (6535.TWO) held its annual shareholders' meeting today (May 28) and provided an update on LT3001, a novel therapy for acute ischemic stroke. The Company has completed multiple clinical studies and has discussed a potential regulatory pathway with the US FDA. A confirmatory imaging study has been approved in Taiwan and is expected to be completed within one year. The Phase 2/3 bridging study led by Shanghai Pharmaceuticals is set to begin in China, with patient enrollment planned for the second half of the year.

According to Lumosa President, Dr. Sheng-Wen Yeh, LT3001 has drawn interest from several global pharmaceutical companies. The Company will will take a measured approach to licensing, with the aim of accelerating regulatory approval and market entry